Streetbeat News

Products Services

EYPT

EyePoint Pharmaceuticals' shares dropped following the announcement that its Phase 2 PAVIA trial of DURAVYU failed to meet its primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:39 am

GRYP

Gryphon Digital Mining, Inc. (NASDAQ:GRYP) reported a record-breaking April 2024 with $2.6M in Bitcoin production, achieving new efficiency milestones. The company, known for its 100% renewable energy mining, produced 40 bitcoins at an average price of $66,183 each. It set new records with an average self-mining hashing power of 914 PH/s and improved machine efficiency to 28.7 J/T, thanks to the installation of Bitmain S21 200 TH/s machines. Gryphon also maintained its top-ranking position in bitcoin efficiency, holding 21 bitcoins in treasury by month-end.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:39 am

GOSS

Gossamer Bio, Inc. (NASDAQ:GOSS) has entered into a $160M partnership with Chiesi Group to develop and commercialize seralutinib for pulmonary hypertension. This collaboration aims to accelerate seralutinib's development, particularly for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Gossamer will lead the development and US commercialization, sharing costs and profits with Chiesi, which will commercialize seralutinib outside the US. Gossamer could receive up to $486M in milestones.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:37 am

ANVS

Annovis Bio, Inc. (ANVS) CEO Maria Maccecchini addressed stockholders following mixed results from a Phase II/III Alzheimer's study, outlining plans for an improved Phase III trial. The company aims to refine patient selection based on plasma AD biomarkers and focus on early and mild Alzheimer's patients, who showed the most improvement in previous studies. Despite the setback, Annovis remains committed to developing treatments for neurodegenerative diseases.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:35 am

GLYC

GlycoMimetics shares dropped following the announcement of topline results from its Phase 3 study of uproleselan in patients with R/R AML and the issuance of preliminary Q1 2024 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:29 am

AAPL

BRK

Ross Gerber, a prominent Tesla Inc. investor, shared his admiration for Warren Buffett's decisive business acumen after Berkshire Hathaway reduced its Apple holdings by 18% in Q1. Gerber's recount of a 2008 interaction with Buffett highlights the latter's tough business approach. The reduction in Apple's stake by Berkshire has led to speculation about Apple's future, amidst discussions on AI's role in shaping the tech giant's strategy. Apple's CEO Tim Cook remains bullish with a significant investment in AI, supported by predictions of an AI-driven super cycle by Wedbush's Dan Ives.

Portfolio Pulse from Rounak Jain

May 06, 2024 | 11:28 am

BMY

The European Medicines Agency has validated the Type 2 variation application for Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer. This validation marks a significant step towards the potential approval and availability of this treatment combination in Europe.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:08 am

OPXS

Optex Systems has received a $3.8 million order for laser protected periscopes, indicating a significant business win for the company.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:06 am

BTCUSD

ETHUSD

Bitcoin (BTC) surpassed 1 billion transactions, 15 years after its creation by Satoshi Nakamoto, marking a historic milestone. The achievement was fueled by the halving day Runes frenzy, boosting transactions significantly. Despite this, Bitcoin's transaction rate remains slower than Ethereum's (ETH), which has processed nearly 2.4 billion transactions, thanks to its smart contracts and decentralized applications. The surge in Bitcoin transactions over the last 15 months is attributed to new token protocols like Ordinals and Runes. The year also saw a sustained demand for Bitcoin, with $11.56 billion moving into U.S. spot exchange-traded products, representing 4.12% of Bitcoin's total supply. Bitcoin's price recently surged from $57,000 to $64,000, yet it's considered to be in a prime buy zone according to crypto analyst Ali Martinez.

Portfolio Pulse from aniketverma@benzinga.com

May 06, 2024 | 11:05 am

CANF

Can-Fite BioPharma Ltd. announced receiving a Notice of Allowance from the European Patent Office for a patent on CF602, a drug candidate for treating erectile dysfunction, particularly in diabetics who cannot use existing drugs.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:04 am